RT Journal Article
T1 A journey through the history of PEGylated drug delivery nanocarriers
A1 López Estévez, Ana María
A1 Gref, Ruxandra
A1 Alonso Fernández, María José
K1 Nanoparticles
K1 PEGylation
K1 Drug targeting
AB This note aims to inspire through providing a personal view of the development and potential Drug Delivery Nanocarriers functionalized with polythyleneglycol (PEG). This polymer has been used extensively in Pharmaceutical Technology in a variety of compositions, including polyethylene oxide (PEO)-based surfactants. However, the concept of PEGylation, which started in the 70’s, differs from the functionality of a surfactant, already discloses in the 50’s. Here, we strictly adhere to the biological functionality of PEGylated nanocarriers intended to have a reduced interaction with proteins and, therefore, modify their biodistribution as well as facilitate their diffusion across mucus and other biological barriers. We analyze how this concept has evolved over the years and the benefit obtained so far in terms of marketed nanomedicines and provide the readers with a prospect view of the topic.
PB Springer
SN 2190-393X
YR 2024
FD 2024
LK http://hdl.handle.net/10347/34654
UL http://hdl.handle.net/10347/34654
LA eng
NO López-Estevez, A.M., Gref, R. & Alonso, M.J. A journey through the history of PEGylated drug delivery nanocarriers. Drug Deliv. and Transl. Res. 14, 2026–2031 (2024). https://doi.org/10.1007/s13346-024-01608-8
DS Minerva
RD 28 abr 2026